Skip to main content
Erschienen in: Pathology & Oncology Research 1/2018

24.02.2017 | Original Article

Expression of Stromal Caveolin- 1 May Be a Predictor for Aggressive Behaviour of Breast Cancer

verfasst von: Nuket Eliyatkin, Safiye Aktas, Gulden Diniz, Halil Hakan Ozgur, Zubeyde Yildirim Ekin, Ali Kupelioglu

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Caveolin-1 (Cav-1) is well known as a principal scaffolding protein of caveolae which are specialized plasma membrane structures. The role of Cav-1 in tumorigenesis of breast cancers is relatively less studied. The aim of the present study is to describe the biological roles of Cav-1 in breast cancers considering its contrasting dual functions as an oncogene and as a tumor suppressor. This study included 71 females with breast cancer who had been histopathologically diagnosed in Private Gunes Pathology Laboratory between the years 2007, and 2012. The mean age is 52.48 ± 12.8 years. Patients were followed up for a mean period of 47.97 ± 20.48 months. We didn’t determine Cav-1 positive tumor cells. In 36 cases (50.7%), there were stromal expressions of Cav-1. In the statistical analysis, there was a statistically significant correlation between Cav-1 expression and ER (p = 0.033), metastasis (p = 0.005), lymphatic invasion (p = 0.000), nodal metastasis (p = 0,003), perinodal invasion (p = 0.003), metastasis (p = 0.005) and survival (p = 0.009). We found that Cav-1 expression is associated with tumor size, histological grade, lymph node involvement. Accordingly, we have suggested that Cav-1 may be a predictive biomarker for breast cancer.
Literatur
2.
Zurück zum Zitat Bravatà V, Cammarata FP, Forte GI, Minafra L (2013) “Omics” of HER2-positive breast cancer. OMICS 7(3):119–129CrossRef Bravatà V, Cammarata FP, Forte GI, Minafra L (2013) “Omics” of HER2-positive breast cancer. OMICS 7(3):119–129CrossRef
3.
Zurück zum Zitat Minafra L, Bravatà V, Forte GI, Cammarata FP, Gilardi MC, Messa C (2014) Gene-expression profiling of epithelial–mesenchymal transition in primary breast cancer cell culture. Anticancer Res 34:2173–2184PubMed Minafra L, Bravatà V, Forte GI, Cammarata FP, Gilardi MC, Messa C (2014) Gene-expression profiling of epithelial–mesenchymal transition in primary breast cancer cell culture. Anticancer Res 34:2173–2184PubMed
4.
Zurück zum Zitat Bravatà V, Stefano A, Cammarata FP, Minafra L, Russo G, Nicolosi S, Pulizzi S, Gelfi C, Gilardi MC, Messa C (2013) Genotyping analysis and 18F-FDG uptake in breast cancer patients: a preliminary research. J Exp Clin Cancer Res 32:23CrossRefPubMedPubMedCentral Bravatà V, Stefano A, Cammarata FP, Minafra L, Russo G, Nicolosi S, Pulizzi S, Gelfi C, Gilardi MC, Messa C (2013) Genotyping analysis and 18F-FDG uptake in breast cancer patients: a preliminary research. J Exp Clin Cancer Res 32:23CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat American Cancer Society: Cancer Facts and Figures (2015) Atlanta, GA, American Cancer Society, 2015 American Cancer Society: Cancer Facts and Figures (2015) Atlanta, GA, American Cancer Society, 2015
6.
Zurück zum Zitat Banin Hirata BK, Oda JM, Losi Guembarovski R, Ariza CB, de Oliveira CE, Watanabe MA (2014) Molecular markers for breast cancer: prediction on tumor behaviour. Dis Markers 2014:513158CrossRefPubMedPubMedCentral Banin Hirata BK, Oda JM, Losi Guembarovski R, Ariza CB, de Oliveira CE, Watanabe MA (2014) Molecular markers for breast cancer: prediction on tumor behaviour. Dis Markers 2014:513158CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Pucci M, Bravatà V (2015) Forte GIet al. Caveolin-1, breast cancer and ionizing radiation. Cancer Genomics Proteomics 12(3):143–152PubMed Pucci M, Bravatà V (2015) Forte GIet al. Caveolin-1, breast cancer and ionizing radiation. Cancer Genomics Proteomics 12(3):143–152PubMed
8.
Zurück zum Zitat Razani B, Woodman SE, Lisanti MP (2002) Caveolae: from cell biology to animal physiology. Pharmacol Rev 4:431–467CrossRef Razani B, Woodman SE, Lisanti MP (2002) Caveolae: from cell biology to animal physiology. Pharmacol Rev 4:431–467CrossRef
9.
Zurück zum Zitat Lisanti MP, Scherer P, Tang Z-L, Sargiacomo M (1994) Caveolae, caveolin and caveolin-rich membrane domains: a signaling hypothesis. Trends Cell Biol 4:231–235CrossRefPubMed Lisanti MP, Scherer P, Tang Z-L, Sargiacomo M (1994) Caveolae, caveolin and caveolin-rich membrane domains: a signaling hypothesis. Trends Cell Biol 4:231–235CrossRefPubMed
11.
Zurück zum Zitat Tlsty TD, Hein PW (2011) Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 11:54–59CrossRef Tlsty TD, Hein PW (2011) Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 11:54–59CrossRef
12.
Zurück zum Zitat WitkiewiczA DA, Sotgia F et al (2009) An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 174:2023–2034CrossRef WitkiewiczA DA, Sotgia F et al (2009) An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 174:2023–2034CrossRef
13.
Zurück zum Zitat Qian N, Ueno T, Kawaguchi-Sakita N et al (2011) Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients. Cancer Sci 102:1590–1596CrossRefPubMed Qian N, Ueno T, Kawaguchi-Sakita N et al (2011) Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients. Cancer Sci 102:1590–1596CrossRefPubMed
14.
Zurück zum Zitat Shan-Wei W, Kan-Lun X, Shu-Qin R, Li-Li Z, Li-Rong C (2012) Overexpression of caveolin-1 in cancer-associated fibroblasts predicts good outcome in breast cancer. Breast Care (Basel) 7(6):477–483CrossRef Shan-Wei W, Kan-Lun X, Shu-Qin R, Li-Li Z, Li-Rong C (2012) Overexpression of caveolin-1 in cancer-associated fibroblasts predicts good outcome in breast cancer. Breast Care (Basel) 7(6):477–483CrossRef
15.
Zurück zum Zitat Sagara Y, Mimori K, Yoshinaga K et al (2004) Clinical significance of Caveolin-1, Caveolin-2 and HER-2/neu mRNA expression in human breast cancer. Br J Cancer 91:959–965CrossRefPubMedPubMedCentral Sagara Y, Mimori K, Yoshinaga K et al (2004) Clinical significance of Caveolin-1, Caveolin-2 and HER-2/neu mRNA expression in human breast cancer. Br J Cancer 91:959–965CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Yang G, Truong LD, Timme TL et al (1998) Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4:1873–1880PubMed Yang G, Truong LD, Timme TL et al (1998) Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4:1873–1880PubMed
17.
Zurück zum Zitat Hurlstone AF, Reid G, Reeves JR et al (1999) Analysis of the Caveolin-1 gene at human chromosome 7q31.1 in primary tumors and tumor-derived cell lines. Oncogene 18:1881–1890CrossRefPubMed Hurlstone AF, Reid G, Reeves JR et al (1999) Analysis of the Caveolin-1 gene at human chromosome 7q31.1 in primary tumors and tumor-derived cell lines. Oncogene 18:1881–1890CrossRefPubMed
18.
Zurück zum Zitat Mercier I, Casimiro MC, Wang C et al (2008) Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: implications for the response to hormonal therapy. Cancer Biol Ther 7:1212–1225CrossRefPubMed Mercier I, Casimiro MC, Wang C et al (2008) Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: implications for the response to hormonal therapy. Cancer Biol Ther 7:1212–1225CrossRefPubMed
19.
20.
Zurück zum Zitat Rao X, Evans J, Chae H et al (2013) CpG island shore methylation regulates caveolin-1 expression in breast cancer. Oncogene 32(38):4519–4528CrossRefPubMed Rao X, Evans J, Chae H et al (2013) CpG island shore methylation regulates caveolin-1 expression in breast cancer. Oncogene 32(38):4519–4528CrossRefPubMed
21.
Zurück zum Zitat Engelman JA, Lee RJ, Karnezis A et al (1998) Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J Biol Chem 273:20448–20455CrossRefPubMed Engelman JA, Lee RJ, Karnezis A et al (1998) Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J Biol Chem 273:20448–20455CrossRefPubMed
22.
Zurück zum Zitat Chung YC, Kuo JF, Wei WC et al (2015) Caveolin-1 dependent endocytosis enhances the chemosensitivity of HER-2 positive breast cancer cells to trastuzumab emtansine (T-DM1). PLoS One 10(7):e0133072CrossRefPubMedPubMedCentral Chung YC, Kuo JF, Wei WC et al (2015) Caveolin-1 dependent endocytosis enhances the chemosensitivity of HER-2 positive breast cancer cells to trastuzumab emtansine (T-DM1). PLoS One 10(7):e0133072CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Park SS, Kim JE, Kim YA, Kim YC, Kim SW (2005) Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology 7(6):625–630CrossRef Park SS, Kim JE, Kim YA, Kim YC, Kim SW (2005) Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology 7(6):625–630CrossRef
24.
Zurück zum Zitat Savage K, Lambros MB, Robertson D et al (2007) Caveolin-1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 13:90–101CrossRefPubMed Savage K, Lambros MB, Robertson D et al (2007) Caveolin-1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 13:90–101CrossRefPubMed
25.
Zurück zum Zitat Huang CF, Yu GT, Wang WM et al (2014) Prognostic and predictive values of SPP1, PAI and caveolin-1 in patients with oral squamous cell carcinoma. Int J Clin Exp Pathol 7(9):6032–6039PubMedPubMedCentral Huang CF, Yu GT, Wang WM et al (2014) Prognostic and predictive values of SPP1, PAI and caveolin-1 in patients with oral squamous cell carcinoma. Int J Clin Exp Pathol 7(9):6032–6039PubMedPubMedCentral
26.
Zurück zum Zitat Chatterjee M, Ben-Josef E, Thomas DG et al (2015) Caveolin-1 is associated with tumor progression and confers a multi-modality resistance phenotype in pancreatic cancer. Sci Rep 12(5):10867CrossRef Chatterjee M, Ben-Josef E, Thomas DG et al (2015) Caveolin-1 is associated with tumor progression and confers a multi-modality resistance phenotype in pancreatic cancer. Sci Rep 12(5):10867CrossRef
27.
Zurück zum Zitat Sayhan S, Diniz G, Karadeniz T, Ayaz D, Kahraman DS, Gokcu M, Yildirim HT (2015) Expression of caveolin-1 in peritumoral stroma is associated histological grade in ovarian serous tumors. Ginekol Pol 6(6):424–428CrossRef Sayhan S, Diniz G, Karadeniz T, Ayaz D, Kahraman DS, Gokcu M, Yildirim HT (2015) Expression of caveolin-1 in peritumoral stroma is associated histological grade in ovarian serous tumors. Ginekol Pol 6(6):424–428CrossRef
Metadaten
Titel
Expression of Stromal Caveolin- 1 May Be a Predictor for Aggressive Behaviour of Breast Cancer
verfasst von
Nuket Eliyatkin
Safiye Aktas
Gulden Diniz
Halil Hakan Ozgur
Zubeyde Yildirim Ekin
Ali Kupelioglu
Publikationsdatum
24.02.2017
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 1/2018
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0212-8

Weitere Artikel der Ausgabe 1/2018

Pathology & Oncology Research 1/2018 Zur Ausgabe

Letter to the Editor

Tribute to Prof. George Klein

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.